# Integrative bioinformatics and experiments identify RIBC2 as a key regulator in the esophageal cancer

## TL;DR

This study identifies RIBC2 as a key driver in esophageal cancer, offering potential for early diagnosis and treatment.

## Contribution

The study introduces RIBC2 as a novel diagnostic and prognostic biomarker for esophageal cancer.

## Key findings

- RIBC2 is upregulated in transformed epithelial cells, EC cell lines, and clinical tumor specimens.
- Silencing RIBC2 inhibits cancer cell proliferation, migration, and invasion.
- High RIBC2 expression correlates with an immune-excluded tumor microenvironment.

## Abstract

Early detection of esophageal cancer (EC) remains a major challenge due to the limited understanding of its initial molecular alterations. Therefore, this study aimed to identify the key molecular drivers involved in EC carcinogenesis. Human normal esophageal epithelial cells were subjected to chronic malignant transformation, followed by assessment of their morphological changes, proliferative capacity, clonogenic potential, migration, and invasion abilities. To elucidate the molecular mechanisms underlying tumorigenesis, transcriptome sequencing was performed and integrated with clinical datasets from two independent EC cohorts. Machine learning algorithms were then applied to pinpoint diagnostic and prognostic gene signatures, which were further validated through comprehensive in vitro and in vivo experiments. Differential expression analysis and machine learning identified RIB43A domain with coiled-coils 2 (RIBC2) as a strong diagnostic and prognostic biomarker for EC. RIBC2 expression was markedly upregulated in chronically transformed epithelial cells, established EC cell lines, and clinical tumor specimens, and its elevation was associated with unfavorable clinicopathological characteristics. Functional studies revealed that silencing RIBC2 significantly inhibited cell proliferation, migration, and invasion in both transformed and EC cells. Moreover, immune profiling indicated that high RIBC2 expression was linked to an immune-excluded tumor microenvironment, implying a potential role in modulating responsiveness to immunotherapy. These findings reveal RIBC2 as a novel driver of EC initiation and progression, highlighting its potential as a biomarker for early diagnosis and as a promising target for therapeutic intervention.